Acorda Therapeutics - Stock Price History | ACOR

Historical daily share price chart and data for Acorda Therapeutics since 2023 adjusted for splits. The latest closing stock price for Acorda Therapeutics as of February 03, 2023 is 0.98.
  • The all-time high Acorda Therapeutics stock closing price was 267.00 on January 26, 2015.
  • The Acorda Therapeutics 52-week high stock price is 2.29, which is 133.7% above the current share price.
  • The Acorda Therapeutics 52-week low stock price is 0.26, which is 73.5% below the current share price.
  • The average Acorda Therapeutics stock price for the last 52 weeks is 0.85.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Acorda Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 0.9581 2.5000 2.5000 0.2767 0.7667 -67.92%
2021 4.5086 3.8000 8.0400 2.3000 2.3900 -42.28%
2020 5.8442 11.7600 14.8800 2.7000 4.1406 -66.17%
2019 47.2710 97.3198 104.8198 9.1200 12.2400 -86.91%
2018 141.5792 135.8997 195.5996 77.6398 93.4798 -27.37%
2017 129.1497 116.9998 180.8996 82.7998 128.6997 14.10%
2016 159.1478 253.4995 253.4995 98.6998 112.7998 -56.05%
2015 208.4589 243.0595 266.9995 154.6797 256.6795 4.67%
2014 202.0247 173.7597 246.4195 167.2797 245.2195 39.97%
2013 198.4824 151.0197 242.6395 151.0197 175.1996 17.46%
2012 148.2223 146.7597 165.7197 129.7197 149.1597 4.28%
2011 150.3752 161.9997 198.4796 112.2598 143.0397 -12.55%
2010 189.5909 152.6997 238.1995 150.2997 163.5597 8.17%
2009 140.7918 122.6398 169.1397 100.4398 151.1997 22.87%
2008 140.5868 130.4397 208.1996 92.3998 123.0598 -6.60%
2007 118.0694 93.6598 153.4197 92.0998 131.7597 38.64%
2006 47.2585 40.3199 120.5398 13.3200 95.0398 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.129B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00